– USA, MA – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors. Dr. Kelley will serve as an independent director and member of the Compensation Committee.
“It is a pleasure to welcome Susan to the Board of Directors at such an exciting time for Deciphera,” said Steve Hoerter, President and CEO of Deciphera. “I look forward to leveraging her vast experience across the spectrum of oncology drug development as we continue to advance the ripretinib program and the rest of our pipeline, including DCC-3014, rebastinib and our recently announced potential first-in-class ULK kinase inhibitor, DCC-3116.”
About Dr Susan Kelley
Dr. Kelley brings to Deciphera over 25 years of experience across all stages of oncology drug research and development. Most recently she served as Chief Medical Officer of the Multiple Myeloma Research Consortium where she led the strategic design and management of clinical trials conducted by leading myeloma clinical research centers in North America. Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head – Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar. Prior to joining Bayer, Dr. Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as Executive Director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute. She currently serves as a member of the Board of Directors at multiple publicly traded companies including VBL Therapeutics, Daré Bioscience, Inc., and ArQule, Inc.
“With its first Phase 3 data readout on the horizon, the coming months will be an important time for Deciphera,” said Dr. Kelley. “I look forward to collaborating with the highly accomplished Board and management team to realize the full potential of its pipeline derived through its novel switch control inhibitor platform.”
Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.
For more information: https://www.deciphera.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.